Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA grants breakthrough therapy designation to Hemlibra for hemophilia A without inhibitors

April 17, 2018

Apellis reports interim data from phase Ib PADDOCK study of APL-2 in PNH

April 17, 2018

NeurOp initiates phase I trial of NP-10679

April 17, 2018

Bristol-Myers Squibb and Janssen collaborate on FXIa inhibitors

April 17, 2018

First cohort dosed in phase I clinical study of PB-2452

April 6, 2018

Patient recruitment ongoing in phase I/II trial of ST-400

April 4, 2018

European Commission grants orphan drug designation to Altemia for sickle cell disease

April 4, 2018

Zeria Pharmaceutical applies for approval of Z-213 in Japan

March 29, 2018

Edge Therapeutics discontinues phase III NEWTON 2 study of EG-1962

March 29, 2018

European Commission expands indication for Feraccru

March 28, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
New biomarker may improve RSV drug screening
BioWorld
Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...